Possible Interaction: Vitamin K and Risedronate

“Exclusion criteria are prior warfarin use, secondary … non-osteoporotic metabolic bone diseases, contraindication for vitamin K2 … risedronate , hyper- or hypoparathyroidism, mental disorders, prevalent vertebral fracture at ≥6 sites, severe degenerative spinal deformation between … and L4, serious heart, liver, or kidney disease, or bisphosphonate use within the previous 6 months.”

“In conclusion, concurrent treatment with vitamin K2 and risedronate was not efficacious compared with monotherapy with risedronate in terms of fracture prevention.”

“On the other hand, the combined administration of risedronate and menatetrenone suppressed the tacrolimus-induced increase in bone resorption, in addition to the significant risedronate-induced decrease in bone formation.”

“The combined administration of risedronate and menatetrenone more significantly improved bone strength properties than risedronate alone.”

“This study suggests that the combined administration of risedronate and menatetrenone improves bone strength in tacrolimus-treated rats by preventing and ameliorating the risedronate-induced suppression of bone formation.”

“ConclusionPrior treatment with MK-4 followed by risedronate significantly increased femur strength in comparison to the OVX controls.”

“ Vitamin K2 and risedronate had additive effects on osteocyte density and lacunar occupancy and a synergistic effect on cortical porosity.”

“The combination therapy with menatetrenone provided an additional improvement of trabecular microstructure to the single use of risedronate.”

“In conclusion, concurrent treatment with vitamin K2 and risedronate was not efficacious compared with monotherapy with risedronate in terms of fracture prevention.”

“Available evidence suggest that risedronate prevents deterioration of the connectivity of the trabeculae in ovariectomized rats, whereas vitamin K2 increase the trabecular thickness, and that a combination of risedronate and vitamin K2 has a synergistic effect on preventing the deterioration of trabecular bone architecture induced by estrogen deficiency.”

“ Vitamin K2 mildly attenuated suppression of bone formation (mineralizing surface) and bone erosion caused by risedronate without affecting trabecular bone mass when administered in combination.”